The DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index.
Human hallucinogen research: guidelines for safety
Open accessAbstract
There has recently been a renewal of human research with classical hallucinogens (psychedelics). This paper first briefly discusses the unique history of human hallucinogen research, and then reviews the risks of hallucinogen administration and safeguards for minimizing these risks. Although hallucinogens are relatively safe physiologically and are not considered drugs of dependence, their administration involves unique psychological risks. The most likely risk is overwhelming distress during drug action ('bad trip'), which could lead to potentially dangerous behaviour such as leaving the study site. Less common are prolonged psychoses triggered by hallucinogens. Safeguards against these risks include the exclusion of volunteers with personal or family history of psychotic disorders or other severe psychiatric disorders, establishing trust and rapport between session monitors and volunteer before the session, careful volunteer preparation, a safe physical session environment and interpersonal support from at least two study monitors during the session. Investigators should probe for the relatively rare hallucinogen persisting perception disorder in follow-up contact. Persisting adverse reactions are rare when research is conducted along these guidelines. Incautious research may jeopardize participant safety and future research. However, carefully conducted research may inform the treatment of psychiatric disorders, and may lead to advances in basic science.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therapeutic outcomes appear strongly influenced by psychological “set” (mindset, expectations, preparation), environmental “setting,” and structured post-session integration (96, 99, 107, 108), highlighting the central role of context, support, and integration in optimizing benefit.”
From The therapeutic role of self-transcendence in moral injury recovery: theory, mechanisms, and clinical implications (2026) · cites this paper as [96]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“are not associated with addiction [9, 11, 12]”
From Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“individuals with a lifetime history of psychotic or bipolar disorders or with a family history of these conditions in first- or second-degree relatives are currently excluded from participation to prevent the risk of inducing a psychotic or a manic episode in those with these conditions or with a potential genetic vulnerability [9].”
From Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, both antipsychotics and benzodiazepines can reduce the acute effects of psychedelics (Johnson et al., 2008).”
From Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response (2024) · cites this paper as Johnson et al., 2008
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“When implemented with appropriate methodological and ethical safeguards (73, 95, 96), these approaches are associated with improvements in psychological well-being, adaptive reappraisal, and meaning reconstruction (36, 57, 65, 97–99).”
From The therapeutic role of self-transcendence in moral injury recovery: theory, mechanisms, and clinical implications (2026) · cites this paper as [96]
The cited source says what the claim attributes to it.
In the citing paper
“These compounds present very low long-term toxicity [9, 10]”
The cited source says what the claim attributes to it.
In the citing paper
“The psychedelic experience comes with an increased sensitivity to internal and external stimuli.”
The cited source says what the claim attributes to it.
In the citing paper
“It follows that the general context of psychedelic administration fundamentally shapes drug response and hence safety, as well as potentially therapeutic efficacy [9, 88].”
The cited source says what the claim attributes to it.
In the citing paper
“Psychedelics generally intensify emotional experience and may give rise to anxiety, dysphoria, fear, panic, or paranoia [9].”
The cited source says what the claim attributes to it.
In the citing paper
“This design is based on the contemporary structure of PAP, which typically involves a three-stage framework encompassing preparation, facilitation, and integration (104).”
From Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol (2025) · cites this paper as [104]
The cited source says what the claim attributes to it.
In the citing paper
“These risks include transient anxiety, panic and, very rarely, prolonged psychosis [42].”
From The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol (2022) · cites this paper as [42]
The cited source says what the claim attributes to it.
In the citing paper
“Due to the potential of psychedelics to elicit profound psychological and emotional responses, providing empathetic support during and after a psychedelic experience represents a fundamental ethical requirement (84, 89).”
From Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects (2024) · cites this paper as [89]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Niacin was used as an active placebo that produces an acute physiological response (flushing) thought to aid in blinding.8,22”
From Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial (2023) · cites this paper as [22]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Self-citation[Drug addiction and drug abuse].
Feuerlein, W. (1969) · PubMed · Cited by 1,415
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789
Jerram, T. C. (1981) · Side effects of drugs annual · doi:10.1016/s0378-6080(81)80009-8 · Cited by 695
DSM‐IV‐TR: Diagnostic and Statistical Manual of Mental Disorders
Chao, R., & Manita, J. (2013) · The Encyclopedia of Cross‐Cultural Psychology · doi:10.1002/9781118339893.wbeccp180 · Cited by 683
Shulgin, A. T., & Shulgin, A. (1991) · Cited by 668
Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Glennon, R. A., Titeler, M., & MCKENNEY, J. D. J. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90436-3 · Cited by 635
Flagged first, then by citations
Research works printed but not linked: 38
- Baggott, MJ, Poster presented at the 2006 meeting of the College on Problems of Drug Dependence
- Blewett, DB, 1959, Handbook for the Therapeutic Use of Lysergic Acid Diethylamide-25: Individual and Group Procedures
- Cohen, S., 1965, Harpers Mag, 231, 69
- Council on Spiritual Practices (2001) Code of ethics for spiritual guides (appendix B). In: Roberts, TB (ed), Psychoactive Sacramentals: Essays on Entheogens and Religion. San Francisco: Council on Spiritual Practices, pp. 250-251.
- Dittrich, A. (1993) Psychological aspects of altered states of consciousness of the LSD type: measurement of their basic dimensions and prediction of individual differences. In: Pletscher, A, Ladewig, D (eds), Fifty years of LSD Concurrent status and perspectives of hallucinogens. New York: Parthenon, pp. 101-118.
- Doblin, R., 1991, J Transpers Psychol, 23, 1
- First, MB, 2001, Structured clinical interview for DSM-IV-TR Axis 1 Disorders Research Version Patient Edition (SCID-I/P) Biometrics Research
- Frecska, E., 2006, Neuropsychopharmacol Hung, 8, 189
- Griffiths, RR, 1980, Adv Subst Abuse, 1, 1
- Grob, CS, 2005, Multidisciplinary Association for Psychedelic Studies (MAPS) Bulletin, 15, 8
- Grof, S., 1977, J Psychohist, 4, 269
- Grof, S., 1980, LSD Psychotherapy
- Gutstein, HB, Akil, H. (2006) Opioid analgesics. In: Brunton, LL, Lazo, JS, Parker, KL (eds), Goodman & Gilman's The Pharmacological Basis of Therapeutics, eleventh ed. New York: McGraw-Hill, pp. 547-590.
- Harvard Mental Health Letter, 2006, Harv Ment Health Lett, 23, 5
- Hidalgo, WT, 1960, Acta Med Venez, 8, 56
- Hoch, PH, 1953, Res Publ Assoc Res Nerv Ment Dis, 32, 287
- Hollister, LE, 1961, Arch Int Pharmacodyn Ther, 130, 42
- Kast, EC, 1964, Anesth Analg, 43, 285
- Kurland, AA, Grof, S., Pahnke, WN, Goodman, LE (1973) Psychedelic drug assisted psychotherapy. In: Goldberg, IK, Malitz, S, Kutscher, AH (eds), Patients With Terminal Cancer Psychotheramacological Agents for the Terminally Ill and Bereaved. New York: Columbia University Press, pp. 86-133.
- Kurland, AA, Pahnke, WN, Unger, S., Savage, C., Goodman, E. (1969) Psychedelic psychotherapy (LSD) in the treatment of the patient with a malignancy. In: Cerletti, A, Bove, FJ (eds), The Present Status of Psychotropic Drugs: Pharmacological and Clinical Aspects . Amsterdam, Holland: Excerpta Medica , pp. 432-434.
- Leary, T., 1964, Psychedelic Rev, 1, 324
- Lerner, AG, 2002, Isr JPsychiatry Relat Sci, 39, 92
- Metzner, R., 1985, Forward
- Metzner, R., 1965, Psychedelic Rev, 5, 3
- Mogar, RE, 1969, Psychedelic Rev, 10, 5
- National Institute on Drug Abuse, 2006, LSD, NIDA Infofacts
- Pahnke, W., Thesis presented to the President and Fellows of Harvard University for the PhD in Religion and Society
- Pahnke, WN, 1969, Int Psychiatry Clin, 5, 149
- Reitman, J., 2004, Rolling Stone Magazine, 944, 62
- Richards, WA, 1980, J Altered States Conscious, 5, 309
- Richards, WA, 2003, Brill, 13, 143
- Richards, WA, 1972, J Transpers Psychol, 4, 121
- Roberts, TB, 1997, Smith. J Transpers Psychol, 29, 99
- Rümmele, W., 1961, Schweiz Arch Neurol Neurochir Psychiatr, 87, 365
- Stolaroff, MJ, 2004, The Secret Chief Revealed: Conversations with Leo Zeff, Pioneer in the Underground Psychedelic Therapy Movement
- Strassman, RJ, 1992, Neuropsychopharmacology, 7, 241
- Strassman, RJ, 2001, DMT: The Spirit Molecule
- 10.1001/jama.1969.03160310037007 · DOI
Cited by
Sorted by citations
Items 101–137 of 137
Morton, E., Sakai, K., Ashtari, A., Pleet, M., Michalak, E. E., & Woolley, J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221131997 · Cited by 78
Ona, G., Kohek, M., Massaguer, T., Gomariz, A., Jiménez, D. F., Dos Santos, R. G., Hallak, J. E. C., Alcázar-Córcoles, M. Á., & Bouso, J. C. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1567961 · Cited by 76
Li, N.-X., Hu, Y.-R., Chen, W.-N., & Zhang, B. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.09.041 · Cited by 72
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
Zeifman, R. J., & Wagner, A. C. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.001 · Cited by 67
Mollaahmetoglu, O. M., Keeler, J., Ashbullby, K. J., Ketzitzidou-Argyri, E., Grabski, M., & Morgan, C. J. A. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.695335 · Cited by 65
Psychiatric risks for worsened mental health after psychedelic use
Marrocu, A., Kettner, H., Weiss, B., Zeifman, R. J., Erritzoe, D., & Carhart-Harris, R. L. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241232548 · Cited by 60
Wolff, M., Mertens, L. J., Walter, M., Enge, S., & Evens, R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211073758 · Cited by 58
Breeksema, J. J., Niemeijer, A., Krediet, E., Karsten, T., Kamphuis, J., Vermetten, E., van den Brink, W., & Schoevers, R. (2024) · Scientific Reports · doi:10.1038/s41598-024-53188-9 · Cited by 58
Luoma, J. B., Sabucedo, P., Eriksson, J., Gates, N., & Pilecki, B. C. (2019) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.10.003 · Cited by 56
Evens, R., Schmidt, M. E., Majić, T., & Schmidt, T. T. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231172254 · Cited by 56
Psychedelic-assisted psychotherapy: Where is the psychotherapy research
Aday, J. S., Horton, D., Fernandes-Osterhold, G., O’Donovan, A., Bradley, E. R., Rosen, R. C., & Woolley, J. D. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06620-x · Cited by 54
Studies with psychedelic drugs in human volunteers
Sellers, E. M., Romach, M. K., & Leiderman, D. B. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.029 · Cited by 42
Lafrance, A., Strahan, E., Bird, B. M., St. Pierre, M., & Walsh, Z. (2021) · Journal of Humanistic Psychology · doi:10.1177/00221678211048049 · Cited by 40
Castro Santos, H., & Gama Marques, J. (2021) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000128 · Cited by 37
The subjective experience of acute, experimentally-induced Salvia divinorum inebriation
Addy, P. H., Garcia-Romeu, A., Metzger, M., & Wade, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115570081 · Cited by 36
Aicher, H. D., Mueller, M. J., Dornbierer, D. A., Suay, D., Elsner, C., Wicki, I., Meling, D., Caflisch, L., Hempe, A., Steinhart, C., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1302559 · Cited by 33
Lancelotta, R. L., & Davis, A. K. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1737763 · Cited by 33
Prevalence and therapeutic impact of adverse life event reexperiencing under ceremonial ayahuasca
Weiss, B., Wingert, A., Erritzoe, D., & Campbell, W. K. (2023) · Scientific Reports · doi:10.1038/s41598-023-36184-3 · Cited by 33
Frymann, T., Whitney, S., Yaden, D. B., & Lipson, J. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.863247 · Cited by 30
Doyle, M. A., Ling, S., Lui, L. M. W., Fragnelli, P., Teopiz, K. M., Ho, R., Di Vincenzo, J. D., Rosenblat, J. D., Gillissie, E. S., Nogo, D., et al. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2063273 · Cited by 27
Okano, L., Jones, G., Deyo, B., Brandenburg, A., & Hale, W. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.965641 · Cited by 24
O'Donnell, K. C., Mennenga, S. E., Owens, L. T., Podrebarac, S. K., Baron, T., Rotrosen, J., Ross, S., Forcehimes, A. A., & Bogenschutz, M. P. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2022.106976 · Cited by 23
Psychedelics for Psychological and Existential Distress in Palliative and Cancer Care
Rosenbaum, D., Boyle, A. B., Rosenblum, A. M., Ziai, S., & Chasen, M. R. (2019) · Current Oncology · doi:10.3747/co.26.5009 · Cited by 23
Davis, A. K., Levin, A. W., Nagib, P. B., Armstrong, S. B., & Lancelotta, R. L. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-068884 · Cited by 21
Calder, A. E., Rausch, B., Liechti, M. E., Holze, F., & Hasler, G. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241278873 · Cited by 20
“In addition, both antipsychotics and benzodiazepines can reduce the acute effects of psychedelics (Johnson et al., 2008).”
BackgroundVanderijst, L., Hever, F., Buot, A., Dauré, C., Benoit, J., Hanak, C., Veeser, J., Morgiève, M., Campanella, S., Kornreich, C., et al. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05502-y · Cited by 13
“…of psychotic or bipolar disorders or with a family history of these conditions in first-or second-degree relatives are currently excluded from participation to prevent the risk of inducing a psychotic or a manic episode in those with these conditions or with a potential genetic vulnerability [9].”
BackgroundInfluentialPsychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer
Barnett, B. S., & Greer, G. R. (2021) · Journal of the Academy of Consultation-Liaison Psychiatry · doi:10.1016/j.jaclp.2020.12.011 · Cited by 13
Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study
Hartong, V., & van Emmerik, A. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2080616 · Cited by 11
“While implementation of appropriate safeguards mitigates these risks (Johnson, Richards, and Griffiths 2008; Studerus et al. 2011), microdosing may circumvent them entirely, as it does not induce the intense experiences that characterize a bad trip (Fadiman 2011).”
BackgroundPrimum non nocere: The onus to characterize the potential harms of psychedelic treatment
Ghaznavi, S., Ruskin, J. N., Haggerty, S. J., King, F., & Rosenbaum, J. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230914 · Cited by 12
Johansen, L., Liknaitzky, P., Nedeljkovic, M., Mastin-Purcell, L., & Murray, G. (2022) · Systematic Reviews · doi:10.1186/s13643-022-01930-7 · Cited by 11
“The purpose of these sessions includes preparing participants for what they may experience during a dosing session and constructive ways to respond to such experiences, establishing rapport between participant and therapists and setting beneficial expectations and intentions for the experience [42].”
BackgroundInfluentialKnock, E., Siefried, K. J., Bedi, G., Albert, S., Day, R. O., Ezard, N., Ross, M., Liknaitzky, P., & Brett, J. (2025) · Addiction · doi:10.1111/add.70187 · Cited by 9
Ching, T. H. W., Grazioplene, R., Pittenger, C., & Kelmendi, B. (2023) · doi:10.31234/osf.io/ba42z · Cited by 6
Tolerability, assessment, and prediction of psilocybin-induced altered states of consciousness
Studerus, E. (2012) · University of Zurich · doi:10.5167/uzh-164092 · Cited by 6
Sabucedo, P., Andión, O., Neimeyer, R. A., Soto-Angona, O., Javkin, J., Haro, J. M., Farré, M., & González, D. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1484736 · Cited by 6
“This design is based on the contemporary structure of PAP, which typically involves a three-stage framework encompassing preparation, facilitation, and integration (104).”
Psychoanalyst attitudes towards psychedelic-assisted therapy
Kraiem, E., Diener, M., Guss, J., Mavrides, L., & Saban, S. (2025) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2024.2359444 · Cited by 4
Fleming, W. H. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1701564
Metadata
- Authors
- Johnson, M., Richards, W., & Griffiths, R.
- Affiliations
- Johns Hopkins University (US)
- Johns Hopkins Bayview Medical Center (US)
- Corresponding author
- Griffiths, RR
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2008-05-30
- Volume
- 22
- Issue
- 6
- Pages
- 603-620
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- PMC
- PMC3056407
- OpenAlex
- W2113099805
- Semantic Scholar
- 554f798f25a69d215bea816211ae014c5319edac
- Cited by
- 1,203
- References
- 154
- Citations by year
- 2026: 128 · 2025: 164 · 2024: 167 · 2023: 152 · 2022: 170 · 2021: 97 · 2020: 84 · 2019: 40 · 2018: 42 · 2017: 37 · 2016: 36 · 2015: 21 · 2014: 18 · 2013: 12 · 2012: 12
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Funders
- National Institute on Drug Abuse (R01DA003889, R01DA03889)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
- Keywords
- hallucinogens, psychedelics, bad trips, psychological distress, psychosis, hallucinogen persisting perception disorder, volunteer screening, adverse drug reactions
- MeSH terms
- Clinical Trials as Topic, Environment, Hallucinogens, Humans, Human Experimentation, Perception, Psychotic Disorders, Research, Safety, Practice Guidelines as Topic, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
